Apogee Therapeutics, Inc.
APGE
$43.96
$2.105.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 76.53% | 90.85% | 79.27% | 121.02% | 125.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.25% | 104.23% | 141.46% | 133.64% | 201.64% |
| Operating Income | -65.25% | -104.23% | -141.46% | -133.64% | -201.64% |
| Income Before Tax | -72.17% | -111.75% | -135.21% | -79.06% | -156.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.43% | -111.81% | -135.21% | -79.06% | -156.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.43% | -111.81% | -135.21% | -79.06% | -156.24% |
| EBIT | -65.25% | -104.23% | -141.46% | -133.64% | -201.64% |
| EBITDA | -64.84% | -- | -- | -- | -- |
| EPS Basic | -48.69% | -79.03% | -70.78% | 84.16% | 74.47% |
| Normalized Basic EPS | -48.46% | -78.97% | -70.75% | 84.16% | 74.47% |
| EPS Diluted | -48.69% | -79.03% | -70.78% | 84.16% | 74.47% |
| Normalized Diluted EPS | -48.46% | -78.97% | -70.75% | 84.16% | 74.47% |
| Average Basic Shares Outstanding | 15.95% | 18.30% | 37.75% | 1,030.30% | 903.80% |
| Average Diluted Shares Outstanding | 15.95% | 18.30% | 37.75% | 1,030.30% | 903.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |